From 1 June 2021, MVASI® brand for bevacizumab will replace the Avastin® brand for all PBS listed items.
This has reduced the authority level, and bevacizumab is now listed as unrestricted benefit. Authority approval isn’t required for prescribing the listed quantity and repeats.
Visit the PBS Schedule, or contact the PBS General Enquiries line for further information.
This information was printed 24 March 2023 from https://www.servicesaustralia.gov.au/glioblastoma. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/site-notices when using this material.